The Clinical Science Program of the Cancer Center of Hawaii is responsible for this institution's contribution to the Southwest Oncology Group activities. The Cancer Center of Hawaii is a free standing research institute of the University of Hawaii. High quality data accession continues to be one of the primary goals and accomplishments of this institution. Scientific contributions have been related to development of Phase II studies and active participation in the discipline and disease committees. The University of Hawaii School of Medicine has established pre- and post-M.D. teaching programs at major hospitals in Honolulu, thereby, assuring dedicated teachers and investigators in each affiliated institution, similar to that of a university medical complex. The various units of the Cancer Center of Hawaii participate in intramural research projects and programs. A patient management system is being developed through cooperative efforts with the Data and Computation Unit of the Center. A multi-user on-line system will be implemented to improve accuracy and timeliness of data accrual and to aid ongoing management of patients on clinical trials. The present Cancer Control Program of the Southwest Oncology Group has identified competent investigators on the outer islands and rural Oahu so that both continuity of patient care and patient entry on clinical trials have been actively pursued. Data management continues to be centralized at the Center to assure quality control.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA032734-05
Application #
3557279
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1982-09-01
Project End
1987-12-31
Budget Start
1986-01-01
Budget End
1986-12-31
Support Year
5
Fiscal Year
1986
Total Cost
Indirect Cost
Name
University of Hawaii
Department
Type
Organized Research Units
DUNS #
121911077
City
Honolulu
State
HI
Country
United States
Zip Code
96822
Gordon, M A; Gundacker, H M; Benedetti, J et al. (2013) Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Ann Oncol 24:1754-61
Tangen, Catherine M; Hussain, Maha H A; Higano, Celestia S et al. (2012) Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346). J Urol 188:1164-9
Scosyrev, Emil; Ely, Benjamin W; Messing, Edward M et al. (2011) Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710). BJU Int 108:693-9
Albain, Kathy S; Barlow, William E; Shak, Steven et al. (2010) Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 11:55-65
Albain, Kathy S; Barlow, William E; Ravdin, Peter M et al. (2009) Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet 374:2055-63
Sonpavde, Guru; Goldman, Bryan H; Speights, V O et al. (2009) Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer 115:4104-9
Beer, Tomasz M; Tangen, Catherine M; Bland, Lisa B et al. (2006) The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer: A multivariate analysis of Southwest Oncology Group Study 8894. Cancer 107:489-96
Hutchins, Laura F; Green, Stephanie J; Ravdin, Peter M et al. (2005) Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-010 J Clin Oncol 23:8313-21
Whitehead, Robert P; Benedetti, Jacqueline K; Abbruzzese, James L et al. (2004) A phase II pilot study of high-dose 24-hour continuous infusion of 5-FU and leucovorin and low-dose PALA for patients with colorectal cancer: a Southwest Oncology Group study. Invest New Drugs 22:467-73
Arpino, Grazia; Green, Stephanie J; Allred, D Craig et al. (2004) HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin Cancer Res 10:5670-6

Showing the most recent 10 out of 24 publications